financetom
Business
financetom
/
Business
/
State Street Signs Cooperation Agreement With Saudi Arabia's Albilad Capital
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
State Street Signs Cooperation Agreement With Saudi Arabia's Albilad Capital
Nov 10, 2025 1:49 AM

04:40 AM EST, 11/10/2025 (MT Newswires) -- State Street (STT) said Monday it signed a cooperation agreement to support Albilad Capital's securities services offerings in Saudi Arabia.

Albilad is the investment arm of Bank Albilad.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Walmart to launch first stores in Africa by year-end
Walmart to launch first stores in Africa by year-end
Sep 9, 2025
By Siyanda Mthethwa JOHANNESBURG (Reuters) -U.S. retailer Walmart ( WMT ) will launch its first branded stores in South Africa this year, it said on Tuesday. The move by Walmart ( WMT ), which already owns South African retail group Massmart, places it in direct competition with established domestic retailers including market leader Shoprite, Woolworths and Pick n Pay. Online,...
MedX Health Extends $2.5 Million Private Placement, Names Paul Matts Strategic Advisor
MedX Health Extends $2.5 Million Private Placement, Names Paul Matts Strategic Advisor
Sep 9, 2025
08:54 AM EDT, 09/09/2025 (MT Newswires) -- MedX Health ( MDXHF ) said overnight Monday it is extending the closing date of its $2.5 million private placement by up to 30 days. The company said it already received conditional acceptance from the TSX Venture Exchange, but closing for the full amount has been delayed. MedX first announced the offering on...
Xilio Therapeutics Starts Phase 2 Trial for Potential Anti-Tumor Monotherapy, Achieves $17.5 Million Development Milestone Under License Deal With Gilead
Xilio Therapeutics Starts Phase 2 Trial for Potential Anti-Tumor Monotherapy, Achieves $17.5 Million Development Milestone Under License Deal With Gilead
Sep 9, 2025
08:53 AM EDT, 09/09/2025 (MT Newswires) -- Xilio Therapeutics ( XLO ) said Tuesday it started phase 2 of an ongoing phase 1/2 clinical trial assessing efarindodekin alfa, a potential monotherapy for patients with certain advanced solid tumors. The company said that in connection with beginning of phase 2, it achieved a $17.5 million development milestone under its exclusive global...
Sector Update: Consumer
Sector Update: Consumer
Sep 9, 2025
08:53 AM EDT, 09/09/2025 (MT Newswires) -- Consumer stocks were mixed pre-bell Tuesday, with the Consumer Staples Select Sector SPDR Fund (XLP) down 0.3% and the Consumer Discretionary Select Sector SPDR Fund (XLY) 0.1% higher. Designer Brands ( DBI ) shares were down more than 1% after the company reported a decline in fiscal Q2 net sales and said it...
Copyright 2023-2026 - www.financetom.com All Rights Reserved